Alpha-Synuclein Mediated Hyperphosphorylation of Tau in the Genesis of

Section: For Industry

Category(ies): CNS Disorders

Reference #: SIAN422002

OTC Contact: David Humphrey (Directory Information | Send a Message)

Description

Georgetown University researchers have shown that alpha-synuclein hyperphosphorylates Tau, through the direct activation of at least two kinases, GSK-3beta and ERK. Hyperphosphorylated Tau has not previously been linked to the genesis of Parkinson’s disease and synucleopathies. Blockade of the hyperphosphorylation of Tau, will be a viable treatment strategy to prevent ongoing neurodegeneration of different brain regions.

Applications

Early stage diagnostic as well as potential treatment of Parkinson’s disease. 

Advantages

Stage of Development

Stage of Development:  Animal studies testing the hypothesis that reducing alpha-synuclein levels or blockade of kinases that hyperphosphorylate Tau, will prevent the degeneration of the nigrostriatal system in toxin models, and will cause arrest or reversal of degenerated neurons are underway.

Inventor:  Dr. Anita Sidhu

Relevant Publications

Relevant Publications:  Duka et al. Alpha-Synuclein induces hyperphosphorylation of Tau in the MPTP model of Parkinsonism.  FASEB Journal 20: 2302-2312 2006.

Patent Status

U.S. and Foreign Rights protected.